Is BioAtla, Inc. (BCAB) a Buy, Sell, or Hold?
BioAtla, Inc.
NASDAQ:BCAB
$4.26 USD
$0.2 (4.93%)
- Volume
- 39.12K
- Average Volume
- 51.71K
- Market Capitalization
- $5.37M
- P/E Ratio
- -0.10
- Dividend Yield
- 0.00%
- Price Target
- $250.00
- Year High
- $71.50
- Year Low
- $3.12
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.15
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Jay Short |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | BCAB |
| CUSIP | 09077B203 |
| CIK | 0001826892 |
| Web | https://www.bioatla.com |
| Phone | 858 558 0708 |
| Currency | USD |
| Employees | 41 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | -0.16 |
| Payout Ratio | 0.00 |
| Current Ratio | 0.15 |
| Quick Ratio | 0.15 |
| Cash Ratio | 0.09 |
Sales & Book Value
| Annual Sales | $2M |
| Price / Sales | 2.69 |
| Cash Flow | -24.76 |
| Price / Cash Flow | -0.14 |
| Price / Book | -0.17 |
Price Target and Rating
| Average Stock Price Forecast | $250.00 |
| High Stock Price Forecast | $250.00 |
| Low Stock Price Forecast | $250.00 |
| Forecast Upside/Downside | -98.30% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 9 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-50.5 |
| Trailing P/E Ratio | -0.10 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $-59.61M |
| Net Margin | -2530.85% |
| Pretax Margin | -2530.85% |
| Return on Equity | 166.67% |
| Return on Assets | -590.91% |
Financials Score
| AltmanZ Score | -110.91 |
| Piotroski Score | 1.00 |
| Working Capital | -17.6M |
| Total Assets | 8.57M |
| Ebit | -48.1M |
| Market Cap | 5.12M |
| Total Liabilities | 45.88M |
Poll Results
About BioAtla, Inc. (NASDAQ:BCAB) Stock
BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer. A third candidate, BA3071, is a conditionally active anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody aimed at a broad spectrum of cancers, including renal cell carcinoma, non-small ... cell and small cell lung cancers, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. Established in 2007, BioAtla Inc. operates out of San Diego, California.
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
2026-05-18 06:45:00
Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license
Frequently Asked Questions
-
What is the current BioAtla, Inc. (BCAB) stock price?
-
BioAtla, Inc.(NASDAQ:BCAB) stock price is $4.26 in the last trading session. During the trading session, BCAB stock reached the peak price of $71.5 while $3.12 was the lowest point it dropped to. The percentage change in BCAB stock occurred in the recent session was 4.93% while the dollar amount for the price change in BCAB stock was $0.2.
-
BCAB's industry and sector of operation?
-
The NASDAQ listed BCAB is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BCAB?
-
Lisa Pelton | Accounting Manager
Sheri Lydick | Chief Commercial Officer
Susie Melody | Senior Vice President of Human Resources
Cathy Chang | Senior Vice President of Research & Development
Jay Short | Co-Founder, Chief Executive Officer & Chairman -
How many employees does BCAB have?
-
Number of BCAB employees currently stands at 41. BCAB operates from 11085 Torreyana Road, San Diego, CA 92121, US.
-
Link for BCAB official website?
-
Official Website of BCAB is: https://www.bioatla.com
-
How do I contact BCAB?
-
BCAB could be contacted at phone #858 558 0708 and can also be accessed through its website. BCAB operates from 11085 Torreyana Road, San Diego, CA 92121, US.
-
How many shares of BCAB are traded daily?
-
The average number of BCAB shares traded daily for last 3 months was 51.71K.
-
What is the market cap of BCAB currently?
-
The market value of BCAB currently stands at $5.37M with its latest stock price at $4.26